CARDIOLOGS
Cardiologs , a global leader in artificial intelligence (AI) cardiology diagnostics, today announced an exclusive distribution agreement in France with MicroPort CRM , for the reselling of its cloud analysis solution for Holter ECGs. MicroPort CRM is a worldwide leader in the conception and distribution of implementable devices for the treatment of heart rhythm disorders and the leader in France of Holter ECG monitoring devices and software. This agreement marks the official launch, at a large scale, of Cardiologs’ European business operations.
As a pioneer in AI-based healthcare, Cardiologs is the first company to obtain a CE mark for an AI-based medical device. Cardiologs’ medical-grade AI automatically identifies cardiac rhythm disorders with a high level of accuracy and in a timely manner, cutting diagnosis and analysis time in half. Thanks to its secure cloud solution, which General Data Protection Regulations (GDPR) compliant and “Hébergeur de Données de Santé” (HDS) certified, the analysis is available in real-time, from everywhere, by all professionals involved in a patient’s care, thus simplifying the logistics of ECG diagnostics.
Cardiologs is device-agnostic and can interpret data from a broad range of cardiac monitoring devices, a choice aligned with the evolution of health tech towards greater openness and interoperability. Already in use in several healthcare facilities, Cardiologs’ solution has been immediately endorsed by the medical staff, as Dr. Laurent Fiorina, rythmolog at Institut Cardiovasculaire de Paris-Sud (France) and medical expert at Cardiologs confirms, “Cardiologs’ solution enabled us to be more efficient and doubled our Holter analysis capacity. We are now capable of providing our patients with fast and accurate ECG analysis. The ease of use was a major reason for the team’s fast endorsement of this new ECG analysis device.”
Yann Fleureau, co-founder and CEO of Cardiologs, said, “We are extremely enthusiastic to partner with MicroPort CRM for the distribution of our unique technology in France. Its leading position in the Holter market combined with the expertise of its business teams, makes MicroPort CRM an ideal business partner to widely distribute Cardiologs’ solution to all the French cardiologists in hospitals as well as in outpatient medical offices.”
Benoît Clinchamps, President of MicroPort CRM, adds: “We are very happy to launch this partnership with Cardiologs which perfectly reflects MicroPort CRM’s strategy: to offer new unique and innovative services that enable healthcare facilities and cardiologists to optimize their time, resources and improve patient diagnostics.”
France Schwarz, Director of Marketing Europe at Cardiologs added, “This agreement confirms our solution’s attractiveness and marks the first phase of our European marketing strategy.”
About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 5 million ECG recordings and is supported by a number of clinical publications.
For more information: https://cardiologs.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005648/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Brings Together Sport Stars and Legends, Leaders and Decision-Makers on the Largest Global Platform to Shape the Future of Sports: the World Sports Summit18.12.2025 14:40:00 CET | Press release
Under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum and the supervision of the Dubai Sports Council- The Summit, under the theme ‘Uniting the World Through Sports’, aligns with the objectives of Dubai Sports Sector Strategic Plan 2033- A comprehensive programme will address the future of sports, development of the sector and more The Dubai Sports Council has announced the launch of the World Sports Summit (WSS), which will take place under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence and Chairman of the Executive Council of Dubai. The event is set to be held from December 29-30, 2025 at Madinat Jumeirah in Dubai, under the theme ‘Uniting the World Through Sports’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218607571/en/ Dubai Brings Together Sport Stars and Legends, Leaders and Decisi
Regula Wins High Customer Marks and Strong Momentum in G2’s Winter 2026 Grid Reports for Identity Verification18.12.2025 14:11:00 CET | Press release
Regula, a global developer of identity verification solutions, has been recognized by customers on G2’s review platform as one of the fastest-rising and most trusted vendors in the identity verification market. Regula is named as a Leader in three G2 Winter 2026 Grid® Reports for Identity Verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218134153/en/ Regula is recognized as a Leader in G2’s Winter 2026 Grid Reports for Identity Verification, reflecting strong customer satisfaction and enterprise-grade IDV capabilities. This season, Regula earned a Leader placement in G2’s Overall Grid® for Identity Verification Software, reflecting strong customer satisfaction and a growing presence in the market. The company was also named a Leader in the Momentum Grid® Report for Identity Verification, highlighting accelerating demand for Regula’s solutions and increasingly positive feedback from users. In addition, Regula a
Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press release
Collaboration to Deliver Safer, Smarter, and Cost-Effective Automation for Warehouses and Factories Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press release
Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical developmentSecond program ST-901, a novel NMDA antagonist, currently in IND-enabling studies and expected to enter Phase 1 development next yearSeries A co-led by Dexcel Pharma and Third Rock Ventures with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorder
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom